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Abstract
Purpose The optimal immune globulin replacement dosages
required over time to minimize infection risks in patients with
Primary Antibody Deficiencies are not definitely established.
As with many interventions, there may be specific subgroups
of patients who are more likely to benefit from treatment with
higher or lower dosages. The aim of the study was to verify
the efficacy of a rationale for individualized immune globulin
utilization and to elucidate the effects of care on patient
outcome.
Methods Single centre interventional study on 108 patients
with Primary Antibody Deficiencies. The objective was to
determine for each patient the best interval between immune
globulins administration in order to:
• Keep IgG trough levels >500 mg/dL,
• Minimize of major infections (pneumonias and infections
requiring hospitalization),
• Minimize of adverse events (AE).
Results Ninthly eight per cent of patients achieved the
objective of the study. Patients who had low switched
memory B cells and low IgA serum levels and/or are
affected by bronchiectasis and/or enteropathy and/or
continued to experience adverse events despite pre-
medications, achieved the study objective by shortening
the administration intervals to 2-weeks or to 1-week
without the need to increase the monthly cumulative
immunoglobulin dosage and its relative cost. The ad-
verse events were reduced by administrating low Ig
dosages in a single setting. Patients without risk factors
achieved the study objective with immune globulin re-
placement administered with the widely used interval of
3 or 4 weeks.
Conclusions The exact timing and optimal immunoglobulin
prophylaxis regimen might be tailored according to clinical
and immunological markers.
Keywords Primary antibody deficiencies . patients’
outcomes . replacement therapy . immunoglobulins .
intervals . dosages . cost
Introduction
Immune globulin (Ig) replacement is the standard therapy for
primary antibody deficiencies (PAD) aiming to replace the
missing antibodies and thereby to prevent recurrent infections
[1–3]. The optimal Ig dosages required over time to minimize
infection risk are not definitely established with a consequent
wide variation in treatment practices [4–6]. Debate continues
regarding the exact timing and the optimal prophylaxis regi-
men [7–9], knowing that the system of care is itself an impor-
tant determinant of patient outcomes. Unfortunately, many
health care delivery systems are subjected to economic pres-
sures. Individualized medicine and personalized health re-
search presents methodological challenges [10]. In PAD dif-
ferent options have been explored to establish how we should
individualize Ig replacement therapy [11–13]. As with many
interventions, there may be specific subgroups of patients [14]
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who are more likely to benefit from treatment with higher or
lower dosages of Ig.
In PAD, we have previously identified [15] a clinical
phenotype characterized by a high risk of acquiring infec-
tions: patients who had low IgG and IgA levels at diag-
nosis; patients who had IgA level <7 mg/dL and who had
bronchiectasis [16]. These data confirmed previous obser-
vations showing that the loss of function of memory B
cells seems to represent the major cause of PAD-
associated clinical conditions [17–20]. Here we show the
results of an interventional single centre study on 108
PAD patients aimed to verify the efficacy of a new ratio-
nale for an individualized intravenous Ig (IVIG) utiliza-
tion in the treatment of symptomatic PADs, Common
Variable Immune Deficiencies (CVIDs) and X-linked
Agammaglobulinemia (XLA). Our hypothesis was that
an adequate patient’s outcome could be achieved by
shorting the administration intervals to 1- or 2-weeks
without the need to greatly increase the monthly cumula-
tive Ig dosage in those PAD patients: 1) who present an
infectious risk profile; 2) who are affected by bronchiec-
tasis and/or enteropathy; 3) who continue to have adverse
events (AE) despite pre-medication.
Materials and Methods
Study Design prospective non-randomized interventional sin-
gle centre study in PAD patients over 1 year period. Study
design was shown in Fig. 1.
Aim of the Study to determine for each patient the optimal
infusion frequency of immune globulins and the Ig cumulative
monthly dosage in order to achieve the following goals:
& maintenance of IgG trough levels >500 mg/dL;
& minimization of major infections (pneumonias and infec-
tions requiring hospitalization);
& minimization of AE IVIG-related.
Group Definition Patients on IVIG were enrolled into two
groups according to the following parameters: serum IgG
trough levels; serum IgA levels; presence of bronchiectasis;
presence of enteropathy; positive history for AE IVIG-related.
& Group 1 (high risk): patients receiving IVIG replacement
every 3 or 4 weeks who had one of the following:
& AEs despite premedication by steroids (hydrocortisone
100–250 mg), paracetamol and anti-hystamine drugs;
& IgG trough levels <500 mg/dL
& IgA <7 mg/dL
& Bronchiectasis
& Enteropathy.
& Group 2 (fewer disease-associated complications): pa-
tients receiving IVIG replacement every 3–4 weeks who
did not meet the criteria listed above.
Patients of group 1 changed to fortnightly infusion with a
constant monthly dosage; patients of group 2 continued to
follow the usual pattern of Ig administration.
After 3 months, an assessment relative to the study objec-
tive was performed: patients of group 1 who did not achieve
the objective changed from fortnightly to weekly infusions;
the cumulative monthly dosage was increased in order to
reach the objective (1-week); patients of group 1 who
achieved the objective remained at the established 2 weeks
interval (2-weeks interval) and did not increase the cumulative
monthly Ig dose. Patients of group 2 who did not achieved the
objective of the study were changed to fortnightly infusion;
patients of group 2 who achieved the objective remained at the
established 3 or 4 weeks intervals.
Data of 13 PAD patients receiving subcutaneous (SCIG)
replacement at the study time were also collected. These
patients continued their schedule of SCIG administration dur-
ing the study time.
Patients We enrolled all 108 patients with primary antibody
deficiency (PAD) attending our Reference Centre for Primary
Immune Deficiencies. Patients were diagnosed according to
the ESID/PAGID criteria for XLA and CVIDs [21]. Ten
patients had a definitive diagnosis of XLA based on <2 % of
peripheral B cells and mutations of the Btk gene; 98 patients
had a diagnosis of CVIDs based on IgG <500 mg/dL, IgA 2
standard deviation (SD) below age-specific reference range,
age onset >4 years, poor response to vaccines and exclusion of
other causes of hypogammaglobulinemia.
A detailed sets of data was available since all patients with
a diagnosis of CVID and XLA have been regularly followed
up in our centre according to the Italian guide-lines (www.
aieop.org) and their clinical and immunological data have
been regularly collected in a national database once a year.
The data set included: age, date of PAD diagnosis, serum IgG,
IgA and IgM levels determined every 3 months, clinical
manifestations, route, doses and intervals of Ig replacement,
occurrence of AE. At the time of this interventional study, we
continued to follow our guidelines collecting for each patient:
full blood counts, chemistry and serum Ig every 3 months;
clinical manifestations once a month. Lymphocyte subsets
phenotype analysis were repeated once at time of the study.
Route, dosage and interval of Ig replacement was recorded
once a month. High-resolution chest Computerised Tomogra-
phy (HRCT) scans was performed once every four years in all
patients according to National guidelines (www.aieop.org).
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All patients have been IVIG or SCIG replacement for at
least 5 years. All participants provided written informed con-
sent. The study protocol was approved by the Institutional
Review Board at University Sapienza of Rome.
Statistical Analysis Parametric and non-parametric data was
presented as mean±SD or range, as indicated. For comparison
between groups, the Student T test and Mann–Whitney test
were used for parametric or non-parametric datasets. We used
SAS, JMP8 version (SAS Institute, Cary, North Carolina), for
all statistical analyses. Results were expressed as hazard ratios
(HR) with 95 % CIs and p values. A p value of <0.05 was
taken as the threshold of statistical significance.
Results
Intervals Between Administrations and Dosages of the Ig
Replacement
Based on the hypothesis that an IgG trough level might be
maintained at higher levels by decreasing the infusion fre-
quency without the need to greatly increase the cumulative
monthly Ig dosage, we established for each patient the optimal
Ig replacement interval necessary to keep the patient free of
major infections and free of AE. Clinical and immunological
data of patients grouped according to the IVIG administration
intervals were shown in Table 1. Data of patients on SCIG
replacement were also shown.
Patients Under IVIG Administered at Short Interval Times: 1
Week or 2 Weeks Intervals
The interval between IVIG administrations was established
every 2 weeks in 56/60 patients who fulfilled the inclusion
criteria of group 1 (“high risk”). Eight patients refused to
shorten the interval between IVIG administrations for logisti-
cal reasons and/or for poor compliance, so they were not
included in the analysis. Thus, the total number of patients
included this group was 48 patients.
After 3 months from the enrolment, a patient assess-
ment relative to the study objective was perform: 42/48
patients achieved the objective and continued to receive
IVIG infusion fortnightly (2-weeks). 6/48 patients did
not achieve the objective: 2 patients couldn’t maintain
IgG trough levels >500 mg/dL because of severe enter-
opathy and 4 patients experienced AEs post-IVIG (back
pain, chills and fever) despite administrations of ste-
roids, paracetamol and anti-histamine drugs before IVIG
infusion; these patients could not tolerate more than 5–
7.5 g of immune globulins per setting. For this reason,
all six reduced the IVIG administration interval to every
week (1-week). Immunological and clinical data of pa-
tients receiving IVIG at 1-week were show in Table 2.
Fig. 1 Flow chart of the study
design. Numbers of patients
enrolled in the different arms of
the study are shown
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Four additional patients from group 2 who did not
achieve the study objective after 3 months changed to
fortnightly infusion.
In summary, at the end of the study six patients received
IVIG weekly (1-week) and 46 patients every two weeks (2-
weeks). The cumulative mean monthly Ig dosage differed
among the groups: 578±70 mg/kg/month (1-week) and 361
±103 mg/kg/month (2-weeks) (p <0.0001, Fig. 2.a). Two
patients affected by a severe enteropathy maintained IgG
trough levels >500 mg/dL by only administering both IVIG
(one infusion/month at 200 mg/kg/month) and SCIG
(100 mg/kg/week). Patients at 1-week interval had more fre-
quently enteropathy (5/6 vs 14/46 p=0.01) and AEs post-
IVIG (5/6 vs 12/46 p=0.005) in comparison to patients at 2-
weeks interval. No differences were observed on the number
of patients with bronchiectasis or IgA levels <7 mg/dL be-
tween these groups.
Patients Under IVIG Administered at Usual Interval Times: 3
Week or 4 Weeks Intervals
Fifty-two out of 108 patients received IVIG administrations
every 3 weeks or 4 weeks; all these patients had a diagnosis of
CVID. None these patients had the clinical phenotype yet
identified as a severe PAD phenotype, that is characterized
by low IgG and IgA levels at diagnosis, IgA level <7 mg/dl,
<2 % of switched memory B cells, presence of bronchiectasis,
and/or enteropathy [15, 16, 22, 23]. Thirty-five patients re-
ceived IVIG every 3 weeks and 17 patients received IVIG
every 4 weeks.
As explained above after 3 months, 4 patients were
changed to fortnightly infusion. In summary, at the end of
the study, 31 patients received IVIG every 3 week (3-week)
and 17 patients every four weeks (4-weeks); all these patients
achieved the study objective. The cumulative mean monthly
Ig dosage did not differ between the 3-weeks and the 4-weeks
intervals: 230±71 mg/kg/month (3-weeks) and 210±
93 mg/kg/month (4-weeks) (Fig. 2a). The cumulative mean
monthly Ig dosages in these patients were lower than the
cumulative mean monthly Ig dosages administered in patients
receiving IVIG weekly or fortnightly (p values shown in
Fig.2a) and lower than the cumulative monthly dosage admin-
istered in patients on SCIG (323±91 mg/kg/month).
Immunological Phenotype of Patients Treated with Longer
or Shorter Intervals
According to the study design, serum IgG trough levels in
the four groups were greater than 500 mg/dL (Fig. 2b and
Table 1): 595±88 mg/dL (1-week); 693±131 mg/dL (2-
weeks); 657±103 mg/dL (3-weeks); 615±84 mg/dL (4-
weeks); in the SCIG group the IgG levels were 641±
164 mg/dL. Mean IgA serum levels reflected the inclusion
criteria. IgA levels differed between the groups: 1±2.5 mg/
Table 1 Clinical and Immunological data of 108 PAD patients grouped according to the IVIG administration intervals. Data on 13 patients treated with





























1-week 6 578±70 595±88 4/2 1±2.5 63±60 0.7±1 518±276 6 5 6 5
2-weeks 46 361±103 693±131 37/8 4±4 133±117 2.6±3.7 619±407 33 14 39 12
3-weeks 31 230±71 657±103 31/0 9±1 177±140 3.5±3.0 567±213 0 0 0 0
4-weeks 17 210±93 615±84 17/0 9.5±2 105±89 8±4.6 541±179 0 0 0 0
SCIG 13 323±91 641±164 16/0 20±19 341±222 7.5±4.9 486±262 2 0 2 1
Table 2 Clinical and immunological data of the six patients who received IVIG replacement weekly





1 500 590 yes no yes yes
2 570 750 yes no yes yes
3 690 540 yes no yes yes
4 510 640 yes no yes yes
5 660* 510 yes yes yes no
6 600* 540 yes yes yes no
*: Cumulative monthly dosage administered by IVIG (200 mg/kg/month) and SCIG (100 mg/kg/week)
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dL (1-week); 4±4 mg/dL (2-weeks); 9±1 mg/dL (3-
weeks); 9.5±2 mg/dL (4-weeks) (p values are shown in
Fig.3a).
Serum IgM and serum IgG at diagnosis did not differed
between the groups.
No significant differences were found in the peripheral B
lymphocyte frequencies within the four groups. Percentages
of peripheral blood switched Bmemory cells differed between
the groups: 1-week: 0.75±1 %; 2-weeks: 2.6±3.7 %; 3-
weeks: 3.5±3 %; 4-weeks 8±4.6 % (p values were shown in
Fig. 3.b). Notably, in our cohort, the prevalence of CVIDs
patients with a severe defect of switched memory B cells in
the peripheral blood reflects that described in the European
cohort in Euroclass paper [24].
No significant differences in the frequencies of peripheral
blood CD3+CD4+ cells were observed within the four
groups, despite a lower frequency observed in the group of
patients who received IVIG at 1-week interval: 518±276/
mm3 (1-week); 619±407/mm3 (2-weeks); 567±213/mm3
(3-weeks); 541±179/mm3 (4-weeks). B cell subsets showed
a high variability in the group of patients on SCIG (Table 1).
This reflected the different criteria we adopted for the SCIG
choice, mainly linked to logistical reasons.
Discussion
The demonstrated success of Ig prophylaxis depends predom-
inantly on maintaining an adequate protection against infec-
tions. Most papers on Ig replacement have concluded that the
therapy should be individualized [4–9, 11–13, 25]. Our study
points to the need to elucidate the effects of care on patient
outcomes, in order to identify what works in which setting and
under what conditions. According to international guidelines
the Igmonthly dose of 300–600mg/kg body weight should be
administer intravenously every 3 or 4 weeks and subcutane-
ously once/twice a week. The trend over the past years has
been to increase the monthly cumulative doses [8, 9, 11, 25].
These general rules might not be optimal for all PAD patients,
Fig. 2 IgG trough levels and cumulative immune globulin monthly
dosages. Cumulative monthly Ig dose (mg/kg/month) administered (a)
and serum IgG trough levels (mg/dL) (b) in PAD patients grouped
according to the replacement intervals of IVIG administration: 1-week,
2-weeks, 3-weeks, 4-weeks. Statistical differences between groups are
shown
Fig. 3 Immunological phenotype of patients treated at different Ig ad-
ministration intervals. (a) IgA serum levels; (b) percentages of peripheral
blood switched B memory B cells (CD19+CD27+IgM-IgD-) in PAD
patients grouped according to the replacement intervals of IVIG admin-
istration: 1-week, 2-weeks, 3-weeks, 4-weeks. Statistical differences be-
tween groups are shown
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due to high clinical and immunological heterogeneity of the
underlying diseases [14]. Moreover, the cost inherent to the
need to increase in all PADpatients the trough IgG level might
not be justified and sustainable for many countries. This
strategy may require an increase on the monthly Ig dose with
the consequent increase of the Ig cost. The pharmacokinetics
of IgG and specific antibodies demonstrated a different half-
life in patients treated at different intervals between infusions
[26]. Trough levels of antibodies with the lowest specific
antibody concentrations rise if regular infusions are given
and the actual trough levels in a regularly infused patient
are likely to be greater than the levels of specific IgG
measured by ELISA in the IVIG preparations [27].
Thus, an important determinant of the efficacy of Ig pro-
phylaxis is the length of time an individual spends with a
lower IgG level as it was show in PAD patients treated with
SCIG [28]. This time is more dependent on the patient’s IgG
half-life and the frequency of dosing than on the amount of the
dose infused. In the clinical practice, it would be ideal to
perform a pharmacokinetics (PK) study in all patients. How-
ever, this would require a significant commitment in time
from the patient. This practical drawback has limited the use
of PK information in clinical practice. Different alternative
options have been attempt. The Oxford choice, for example,
was to increase the IVIG dose by 0.15 g/kg/month when
patients present with a serious infection, or 3 or more moder-
ate infections over a year [13]. This recommendation could be
an alternative for patients who have persistent infections;
although other factors such as protein loosing conditions,
airway and intestinal inflammation, need to be assessed when
defining the individual Ig schedule of treatment. Moreover, in
PAD, several lines of experimental evidence gathered recently
[29] provided a basis for an active role for IVIG in
immunomodulation beside the main role to replace the miss-
ing antibodies. IVIG has an active role in regulating autoim-
mune and inflammatory responses through modulating B and
other cells functions [30, 31]. These new findings might help
to explain the different results found in trails aimed to estab-
lish the clinical outcome of Ig replacement in PAD patients. It
is possible that some of the positive effects observed in pa-
tients treated with higher doses are not dependent only on the
prophylactic role of immune globulins but also on the anti-
inflammatory ones [32]. However, higher Ig dosages can
potentially cause side effects [33]. The results of this study
showed that in patients with fewer CVIDs-associated compli-
cations the Ig replacement could be administer with the widely
used interval of 3 or 4 weeks, even administering low Ig
replacement dosages. On the opposite, in patients with a
severe clinical and immunological phenotype the protective
effect might be achieved by lowering the interval between
administrations to 2 weeks and in few cases to 1 week, without
increasing the cumulative monthly Ig dosage and its relative
cost. We also demonstrated that the occurrence of adverse
events in patients who do not tolerate Ig despite pre-
medication might be greatly reduce by decreasing the Ig doses
administered in one setting with a reduced interval between
administrations.
This workup may help to expand access to prophylaxis in
healthcare systems with limited resources and potentially
improve patient outcomes. The extra day/month used for Ig
therapy might be consider costly both for patients and for
health care. However, in Italy, patients with severe chronic
diseases benefit of 3 days off work/month for treatments
without any loss of their salary.
Health care delivery systems are quickly changing in re-
sponse to economic pressures and concerns about quality of
care. The system of care is itself an important determinant of
patient outcomes. The promise of individualized medicine has
launched a huge research enterprise to explore the personal
characteristics that influence responses to therapy [10].We are
challenging our beliefs through real data coming from our
current practice using a latent therapeutic demand for Ig.
Our results are in agreement with the subcutaneous Ig
replacement data. However, differently than the subcutaneous
administration, the intravenous administration might allow to
maintain the protective and immune-modulatory effects due to
the serum IgG peak reached at the time of each administration.
In patients who did not achieve a satisfactory efficacy, both
intravenous and subcutaneous Ig might be administered. We
concluded that the suggested protective high trough IgG level
should not be considered a general goal and only large pro-
spective multi-centre studies might help to clarify which
CVIDs subgroups are at high infection risk. More work is
necessary to define which PAD-associated conditions need a
higher or lower monthly Ig dosage and the best interval
between administrations. However, the considerations
expressed above have a vast potential to ameliorate the clinical
practice of Ig replacement treatment.
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